Show simple item record

dc.contributor.authorMooz, Jen_US
dc.contributor.authorRiegel, Ken_US
dc.contributor.authorPs, Hen_US
dc.contributor.authorSadanandam, Aen_US
dc.contributor.authorMarini, Fen_US
dc.contributor.authorKlein, Men_US
dc.contributor.authorWerner, Uen_US
dc.contributor.authorRoth, Wen_US
dc.contributor.authorWilken-Schmitz, Aen_US
dc.contributor.authorTegeder, Ien_US
dc.contributor.authorRajalingam, Ken_US
dc.date.accessioned2022-05-25T13:24:50Z
dc.date.available2022-05-25T13:24:50Z
dc.date.issued2022-03-18en_US
dc.identifier.citationScience advances, 2022, 8 (11), pp. eabk1538 - ?en_US
dc.identifier.issn2375-2548en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5142
dc.identifier.eissn2375-2548en_US
dc.identifier.doi10.1126/sciadv.abk1538en_US
dc.description.abstractRAF kinases are highly conserved serine/threonine kinases, and among the three RAF isoforms (ARAF, BRAF, and CRAF), the pathophysiological relevance of ARAF is not well defined. Here, we show that patients with lung cancer exhibit low expression of ARAF, which is associated with lymph node metastasis and poor patient survival. We uncover that depletion of ARAF promotes anchorage-independent growth and metastasis through activation of AKT signaling in a subset of lung cancer cells. We identified that loss of ARAF was associated with an increase in ERBB3 expression in a kinase-independent manner. ARAF suppressed the promoter activity of ERBB3, and reconstitution of ARAF in ARAF-depleted cells led to the reversal of enhanced ERBB3-AKT signaling. Furthermore, ARAF inhibited neuregulin 1 (hNRG1)-mediated AKT activation through controlling ERBB3 expression via the transcription factor KLF5. Our results disclose a critical dual role for ARAF kinase in the negative regulation of ERBB3-AKT signaling, thereby suppressing tumor metastasis.en_US
dc.formatPrint-Electronicen_US
dc.format.extenteabk1538 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.titleARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1126/sciadv.abk1538en_US
rioxxterms.licenseref.startdate2022-03-18en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfScience advancesen_US
pubs.issue11en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine
pubs.publication-statusPublisheden_US
pubs.volume8en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSystems and Precision Cancer Medicine
dc.contributor.icrauthorSadanandam, Anguraj


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record